David M. Wilson

Hasselt University — Belgium

Medicine · Health Sciences

64h-index17.5kcitations661works0.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Radiopharmaceutical Chemistry and Applications(196), Prostate Cancer Treatment and Research(124), Multiple Myeloma Research and Treatments(100), Chemical Synthesis and Analysis(100), Nanoplatforms for cancer theranostics(49)

Publications658 total

Role of mitochondria in neuronal function and survival in the enteric and central nervous systems
Cellular and Molecular Life Sciences·2026Open Access
Regioselective Glycosylation of Fluorine-18-Labeled Sorbitol for Enhanced Bacterial Detection In Vivo Using PET
JACS Au·2025· 1 citedOpen Access
Figure S10 from Treatment of Prostate Cancer with CD46-targeted <sup>225</sup>Ac Alpha Particle Radioimmunotherapy
2025Open Access
Figure S3 from Treatment of Prostate Cancer with CD46-targeted <sup>225</sup>Ac Alpha Particle Radioimmunotherapy
2025Open Access
Figure S2 from Treatment of Prostate Cancer with CD46-targeted <sup>225</sup>Ac Alpha Particle Radioimmunotherapy
2025Open Access
Figure S5 from Treatment of Prostate Cancer with CD46-targeted <sup>225</sup>Ac Alpha Particle Radioimmunotherapy
2025Open Access
Figure S1 from Treatment of Prostate Cancer with CD46-targeted <sup>225</sup>Ac Alpha Particle Radioimmunotherapy
2025Open Access
Figure S11 from Treatment of Prostate Cancer with CD46-targeted <sup>225</sup>Ac Alpha Particle Radioimmunotherapy
2025Open Access
Supplementary Data 1 from Treatment of Prostate Cancer with CD46-targeted <sup>225</sup>Ac Alpha Particle Radioimmunotherapy
2025Open Access
Figure S4 from Treatment of Prostate Cancer with CD46-targeted <sup>225</sup>Ac Alpha Particle Radioimmunotherapy
2025Open Access
Figure S6 from Treatment of Prostate Cancer with CD46-targeted <sup>225</sup>Ac Alpha Particle Radioimmunotherapy
2025Open Access
Figure S7 from Treatment of Prostate Cancer with CD46-targeted <sup>225</sup>Ac Alpha Particle Radioimmunotherapy
2025Open Access
Figure S8 from Treatment of Prostate Cancer with CD46-targeted <sup>225</sup>Ac Alpha Particle Radioimmunotherapy
2025Open Access
Figure S9 from Treatment of Prostate Cancer with CD46-targeted <sup>225</sup>Ac Alpha Particle Radioimmunotherapy
2025Open Access
Development and characterization of a potent and selective BLIMP1 protac as a novel, first-in-class therapy for multiple myeloma
Blood·2025Open Access
Selective treatment of acute myeloid leukemia targeting the activated conformation of integrin beta2 with [225Ac]Macropa-PEG4-7065
Nuclear Medicine and Biology·2025Open Access
Effective imaging and treatment of Acute Myeloid Leukemia with radiotheranostics targeting the activated conformation of integrin-β2
2025Open Access
An Integrated 1H/2H Multichannel Head Coil for Improved Deuterium Metabolic Imaging
Proceedings on CD-ROM - International Society for Magnetic Resonance in Medicine. Scientific Meeting and Exhibition/Proceedings of the International Society for Magnetic Resonance in Medicine, Scientific Meeting and Exhibition·2025
Discovery of AZD8421: A Potent CDK2 Inhibitor with Selectivity Against Other CDK Family Members and the Human Kinome
Journal of Medicinal Chemistry·2025· 2 cited
Development of 18F-labelled Zinc Biosensors and PET Imaging
Nuclear Medicine and Biology·2025
page 1 of 33Next →

Frequent Co-authors

A. Collier Cameron(14), R. G. West(14), B. Enoch(14), C. Hellier(14), K. Horne(14), Tim Lister(14), N. Parley(13), R. A. Street(12), C. A. Haswell(12), Jonathan Irwin(12), P. F. L. Maxted(12), P. J. Wheatley(12), Leslie Hebb(11), D. J. Christian(11), B. Smalley(11), I. Skillen(10), D. Queloz(10), D. Pollacco(9), S. Udry(9), D. R. Anderson(9)